Omeros to Announce Q1 Financial Results on May 15, 2024

Omeros Corporation, a NASDAQ-listed biopharmaceutical company, recently announced that it will release its financial results for the quarter and year ending March 31, 2024. The announcement is scheduled for Wednesday, May 15, 2024, after the market closes. Following the release, Omeros will hold a conference call and webcast on the same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to elaborate on the financial results and discuss recent developments within the company.

To join the live webcast of the conference call, interested parties can visit Omeros’ official website. For those opting to join via phone, participants need to register through a specified link to receive a unique PIN. This PIN can either be used to dial into the conference line provided at the registration site or utilized with the "Call Me" feature to receive an instant call on the provided phone number. If participants misplace their PIN or registration confirmation email, they can re-register to obtain a new PIN. A replay of the call will also be accessible online for those who cannot attend the live event.

Omeros Corporation is renowned for its dedication to discovering, developing, and commercializing small-molecule and protein therapeutics aimed at treating both large-market and orphan indications. The company's primary focus is on immunologic disorders, which include complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ leading MASP-2 inhibitor, narsoplimab, is designed to target the lectin pathway of complement and is currently under review by the FDA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Further advancing its drug development programs, Omeros is conducting a Phase 1 multi-ascending-dose clinical trial for OMS1029, a long-acting MASP-2 inhibitor. Additionally, the company's MASP-3 inhibitor, OMS906, is progressing towards Phase 3 clinical trials aimed at treating paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy.

In collaboration with the National Institute on Drug Abuse, Omeros is also working on OMS527, a lead phosphodiesterase 7 inhibitor being developed to treat cocaine use disorder. This compound is additionally being examined for its potential in treating other addictions and addressing significant complications arising from treatments for movement disorders.

Omeros Corporation’s extensive portfolio includes novel immuno-oncology programs that feature both cellular and molecular platforms, demonstrating the company’s broad-reaching efforts in the biopharmaceutical sector.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!